Neurocrine Biosciences (NBIX) Income from Continuing Operations (2009 - 2026)
Neurocrine Biosciences' Income from Continuing Operations was $206.5 million in Q3 2026, down 1.4% from $209.5 million a year earlier but up 43.0% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Income from Continuing Operations (2009 - 2026) Analysis & Trends
On a trailing twelve-month basis, Neurocrine Biosciences' Income from Continuing Operations was $702.5 million through Sep 30, 2026, up 64.1% year-over-year; for FY2025, it came in at $478.6 million, up 40.2% from FY2024.
- Income from Continuing Operations has now increased for four consecutive years, with a five-year compound annual growth rate of 3.3% (FY2020 to FY2025).
- In earlier years, Income from Continuing Operations was $341.3 million in FY2024 (+36.7%), $249.7 million in FY2023 (+61.6%), $154.5 million in FY2022 (+72.4%) and $89.6 million in FY2021 (-78.0%).
- Quarterly Income from Continuing Operations has moved between -$76.6 million (Q1 2023) and $209.5 million (Q3 2025) over five years.
- Compared with a year earlier, Income from Continuing Operations was higher in four of the last seven quarters, with growth averaging 13.8%.
- The best year-over-year quarter for Income from Continuing Operations over five years was Q3 2022 (growth of 204.4%); the worst was Q1 2025 (a decline of 81.8%).
- Per Business Quant data, NBIX's Income from Continuing Operations in the three quarters before Q3 2026 was $144.4 million (Q2 2026), $197.9 million (Q1 2026) and $153.7 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.07 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 4.80 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 3.86 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.25 Bn |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn | 205.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 205.80 Mn |
| Jun 30, 2026 | 149.10 Mn |
| Mar 31, 2026 | 185.20 Mn |
| Dec 31, 2025 | 153.60 Mn |
| Sep 30, 2025 | 210.20 Mn |
| Jun 30, 2025 | 111.00 Mn |
| Mar 31, 2025 | 11.10 Mn |
| Dec 31, 2024 | 94.40 Mn |
| Sep 30, 2024 | 141.80 Mn |
| Jun 30, 2024 | 64.20 Mn |
| Mar 31, 2024 | 39.70 Mn |
| Dec 31, 2023 | 156.40 Mn |
| Sep 30, 2023 | 82.50 Mn |
| Jun 30, 2023 | 97.10 Mn |
| Mar 31, 2023 | -76.60 Mn |
| Dec 31, 2022 | 95.10 Mn |
| Sep 30, 2022 | 66.70 Mn |
| Jun 30, 2022 | -16.90 Mn |
| Mar 31, 2022 | 6.30 Mn |
| Dec 31, 2021 | -9.40 Mn |
API Access
Neurocrine Biosciences Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();